Carvedilol Failed to Improve Episodic Memory in Alzheimer’s Patients

Carvedilol Failed to Improve Episodic Memory in Alzheimer’s Patients
Results from a pilot Phase 4 clinical trial evaluating the potential benefit of a known blood pressure and heart failure treatment, carvedilol, in Alzheimer’s disease showed the medicine had no effect in the episodic memory of patients. However, carvedilol was able to prevent the increase of beta-amyloid levels in cerebrospinal fluid. Alzheimer’s disease is caused by abnormal and toxic accumulations of proteins, such as beta-amyloid and tau proteins, which interfere with the communication between nerve cells. Beta-amyloid peptide 42 (Abeta 42) is the most toxic form of beta-amyloid aggregates and is considered a primary driver for  developing the disease. Carvedilol
Subscribe or to access all post and page content.